These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21907108)

  • 1. Regulatory considerations for clinical mass spectrometry: multiple reaction monitoring.
    Boja ES; Rodriguez H
    Clin Lab Med; 2011 Sep; 31(3):443-53. PubMed ID: 21907108
    [No Abstract]   [Full Text] [Related]  

  • 2. The analysis of native proteins and peptides in the clinical lab using mass spectrometry.
    Bystrom CE
    Clin Lab Med; 2011 Sep; 31(3):397-405. PubMed ID: 21907105
    [No Abstract]   [Full Text] [Related]  

  • 3. Guidelines for reporting the use of mass spectrometry in proteomics.
    Taylor CF; Binz PA; Aebersold R; Affolter M; Barkovich R; Deutsch EW; Horn DM; Hühmer A; Kussmann M; Lilley K; Macht M; Mann M; Müller D; Neubert TA; Nickson J; Patterson SD; Raso R; Resing K; Seymour SL; Tsugita A; Xenarios I; Zeng R; Julian RK
    Nat Biotechnol; 2008 Aug; 26(8):860-1. PubMed ID: 18688232
    [No Abstract]   [Full Text] [Related]  

  • 4. Guidelines for reporting the use of mass spectrometry informatics in proteomics.
    Binz PA; Barkovich R; Beavis RC; Creasy D; Horn DM; Julian RK; Seymour SL; Taylor CF; Vandenbrouck Y
    Nat Biotechnol; 2008 Aug; 26(8):862. PubMed ID: 18688233
    [No Abstract]   [Full Text] [Related]  

  • 5. PSAQ™ standards for accurate MS-based quantification of proteins: from the concept to biomedical applications.
    Picard G; Lebert D; Louwagie M; Adrait A; Huillet C; Vandenesch F; Bruley C; Garin J; Jaquinod M; Brun V
    J Mass Spectrom; 2012 Oct; 47(10):1353-63. PubMed ID: 23019168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass spectrometry for clinical toxicology: therapeutic drug management and trace element analysis.
    Rockwood AL; Johnson-Davis KL
    Clin Lab Med; 2011 Sep; 31(3):407-28. PubMed ID: 21907106
    [No Abstract]   [Full Text] [Related]  

  • 7. Guidelines for experimental design and data analysis of proteomic mass spectrometry-based experiments.
    Barnouin K
    Amino Acids; 2011 Feb; 40(2):259-60. PubMed ID: 20886359
    [No Abstract]   [Full Text] [Related]  

  • 8. Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration.
    Regnier FE; Skates SJ; Mesri M; Rodriguez H; Tezak Z; Kondratovich MV; Alterman MA; Levin JD; Roscoe D; Reilly E; Callaghan J; Kelm K; Brown D; Philip R; Carr SA; Liebler DC; Fisher SJ; Tempst P; Hiltke T; Kessler LG; Kinsinger CR; Ransohoff DF; Mansfield E; Anderson NL
    Clin Chem; 2010 Feb; 56(2):165-71. PubMed ID: 20007858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mass spectrometry-based targeted quantitative proteomics: achieving sensitive and reproducible detection of proteins.
    Boja ES; Rodriguez H
    Proteomics; 2012 Apr; 12(8):1093-110. PubMed ID: 22577011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Good mass spectrometry and its place in good science.
    Duncan MW
    J Mass Spectrom; 2012 Jun; 47(6):795-809. PubMed ID: 22707172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved and emerging gel-free separation and detection methods for proteomics.
    Stastna M; Van Eyk JE
    Proteomics; 2012 Oct; 12(19-20):2902-3. PubMed ID: 23081939
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical proteomics: the promises and challenges of mass spectrometry-based biomarker discovery.
    deVera IE; Katz JE; Agus DB
    Clin Adv Hematol Oncol; 2006 Jul; 4(7):541-9. PubMed ID: 17147241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass spectrometers for the analysis of biomolecules.
    Baldwin MA
    Methods Enzymol; 2005; 402():3-48. PubMed ID: 16401505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PSI-MOD community standard for representation of protein modification data.
    Montecchi-Palazzi L; Beavis R; Binz PA; Chalkley RJ; Cottrell J; Creasy D; Shofstahl J; Seymour SL; Garavelli JS
    Nat Biotechnol; 2008 Aug; 26(8):864-6. PubMed ID: 18688235
    [No Abstract]   [Full Text] [Related]  

  • 15. Regulatory perspective on translating proteomic biomarkers to clinical diagnostics.
    Li J; Kelm KB; Tezak Z
    J Proteomics; 2011 Nov; 74(12):2682-90. PubMed ID: 21856459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is mzXML good for?
    Lin SM; Zhu L; Winter AQ; Sasinowski M; Kibbe WA
    Expert Rev Proteomics; 2005 Dec; 2(6):839-45. PubMed ID: 16307524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass spectrometry based proteomic profiling for pancreatic cancer.
    Pawa N; Wright JM; Arulampalam TH
    JOP; 2010 Sep; 11(5):423-6. PubMed ID: 20818108
    [No Abstract]   [Full Text] [Related]  

  • 18. Group-DIA: analyzing multiple data-independent acquisition mass spectrometry data files.
    Li Y; Zhong CQ; Xu X; Cai S; Wu X; Zhang Y; Chen J; Shi J; Lin S; Han J
    Nat Methods; 2015 Dec; 12(12):1105-6. PubMed ID: 26436481
    [No Abstract]   [Full Text] [Related]  

  • 19. 24-hour lock mass protection.
    Lee KA; Farnsworth C; Yu W; Bonilla LE
    J Proteome Res; 2011 Feb; 10(2):880-5. PubMed ID: 21133379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restructuring proteomics through verification.
    Boja E; Rivers R; Kinsinger C; Mesri M; Hiltke T; Rahbar A; Rodriguez H
    Biomark Med; 2010 Dec; 4(6):799-803. PubMed ID: 21133699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.